⚡ Customer Data Platforms in the United States
Customer Data Platforms (CDPs) are software systems that combine data from multiple sources to create a centralized, persistent customer database that can be accessed and used by other applications.
The United States of America (USA) is a North American country with a population of over 341 million people.
According to our data, customer data platforms are used on 4.9% of websites from the United States.
⭐ Most Popular in 2026
The following chart shows the top CDPs in the United States in 2026, based on market share.
The most popular is Klaviyo with a share of 27.9%, followed by
Snowplow with 24.1% and
Adobe Experience Platform with 16.5%.
Klaviyo 27.9%
Snowplow 24.1%
Adobe Experience Platform 16.5%
Salesforce Marketing Cloud 8.3%
Tealium 7.8%Segment 4.7%
Optimizely 4.5%
Epsilon 2%
Acquia 2%Clearbit 1.4%
BlueConic 1.1%
Listrak 1.1%
Rudderstack 1%- Sitefinity Insight 1%
Zeta Marketing Platform 0.9%
🚀 Highlights
Here is a list of the top CDPs that are more popular in the United States than worldwide.
Differences between global and country rankings are shown in parentheses.
- 2.
Snowplow (-1)
- 8.
Epsilon (-2)
- 10.
Clearbit (-2)
- 11.
BlueConic (-5)
- 12.
Listrak (-11)
- 14. Sitefinity Insight (-6)
- 15.
Zeta Marketing Platform (-3)
- 16.
Omeda (-3) - 18.
Freshpaint (-14)
- 19.
Lytics (-9)
✨ Best CDPs
Below is a more detailed list of the top 25 of the 63 CDPs used on sites from the United States, ranked by their market share.
👉 See Also
- 🌎 CDP in other countries
🗃️ About This Data
- We evaluate the popularity of technologies based on the number of websites where we detect their usage.
- Technologies without a detectable web footprint, and those we do not track, are not reflected in the calculated market share.
- This report is based on the analysis of 579,597 websites from the United States.
- We currently track the presence of 71 CDPs across the web.
- Of these, 63 were detected on websites from the United States.
- Statistics were last calculated on .
- For more details, see our methodology and disclaimer.